Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).

CAS  PubMed  Article  Google Scholar 

Touat, M., Idbaih, A., Sanson, M. & Ligon, K. L. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann. Oncol. 28, 1457–1472 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Eckel-Passow, J. E. et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N. Engl. J. Med. 372, 2499–2508 (2015).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Jaunmuktane, Z. et al. Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. Acta Neuropathol. Commun. 7, 24 (2019).

PubMed  PubMed Central  Article  Google Scholar 

Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469–474 (2018).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231–1251 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550–563 (2016).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).

Article  CAS  Google Scholar 

Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–477 (2013).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Barthel, F. P. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576, 112–120 (2019).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110 (2010).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wang, Q. et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32, 42–56 (2017).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Klughammer, J. et al. The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat. Med. 24, 1611–1624 (2018).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).

CAS  PubMed  Article  Google Scholar 

de Souza, C. F. et al. A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence. Cell Rep. 23, 637–651 (2018).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Haber, D. A. & Schimke, R. T. Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes. Cell 26, 355–362 (1981).

CAS  PubMed  Article  Google Scholar 

Bigner, S. H., Friedman, H. S., Vogelstein, B., Oakes, W. J. & Bigner, D. D. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res. 50, 2347–2350 (1990).

CAS  PubMed  Google Scholar 

Schwab, M. et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305, 245–248 (1983).

CAS  PubMed  Article  Google Scholar 

Turner, K. M. et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 543, 122–125 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Verhaak, R. G. W., Bafna, V. & Mischel, P. S. Extrachromosomal oncogene amplification in tumour pathogenesis and evolution. Nat. Rev. Cancer 19, 283–288 (2019).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Paulsen, T., Kumar, P., Koseoglu, M. M. & Dutta, A. Discoveries of extrachromosomal circles of DNA in normal and tumor cells. Trends Genet. 34, 270–278 (2018).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Storlazzi, C. T. et al. Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. Genome Res. 20, 1198–1206 (2010).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kim, H. et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat. Genet. 52, 891–897 (2020).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Yi, E. et al. Live-cell imaging shows uneven segregation of extrachromosomal DNA elements and transcriptionally active extrachromosomal DNA hubs in cancer. Cancer Disco. 12, 468–483 (2021).

Article  Google Scholar 

Wu, S. et al. Circular ecDNA promotes accessible chromatin and high oncogene expression. Nature 575, 699–703 (2019).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hung, K. L. et al. ecDNA hubs drive cooperative intermolecular oncogene expression. Nature 600, 731–736 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Nathanson, D. A. et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343, 72–76 (2014).

CAS  PubMed  Article  Google Scholar 

deCarvalho, A. C. et al. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nat. Genet. 50, 708–717 (2018).

CAS  PubMed  PubMed Central  Article  Google Scholar 

White, K. et al. New hints towards a precision medicine strategy for IDH wild-type glioblastoma. Ann. Oncol. 31, 1679–1692 (2020).

CAS  PubMed  Article  Google Scholar 

Zhao, H. F. et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol. Cancer 16, 100 (2017).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Liu, E. K., Sulman, E. P., Wen, P. Y. & Kurz, S. C. Novel therapies for glioblastoma. Curr. Neurol. Neurosci. Rep. 20, 19 (2020).

PubMed  Article  Google Scholar 

Dresemann, G. et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J. Neurooncol. 96, 393–402 (2010).

CAS  PubMed  Article  Google Scholar 

Wick, W. et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28, 1168–1174 (2010).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ma, D. J. et al. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol. 17, 1261–1269 (2015).

CAS  PubMed  Article  Google Scholar 

Westphal, M. et al. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur. J. Cancer 51, 522–532 (2015).

CAS  PubMed  Article  Google Scholar 

Reardon, D. A. et al. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 17, 430–439 (2015).

CAS  PubMed  Google Scholar 

Westphal, M., Maire, C. L. & Lamszus, K. EGFR as a target for glioblastoma treatment: an unfulfilled promise. CNS Drugs 31, 723–735 (2017).

CAS  PubMed  PubMed Central  Article